CSI Market
Sign In | Register

Mosaic Immunoengineering Inc (PTSC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PTSC Annual Cash Flow →
A period-by-period view of cash flow from Mosaic Immunoengineering Inc to Jun 30 2025 helps clarify how Jun 30 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-0.35
Depreciation & amortization0.00
Amortization of Other Assets0.00
Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Fair Value Of Common Stock Issued Under License Option Agreement-
Derivative Gain Loss On Derivative Net-
Noninterest Expense-
Gain On Redemption Of Preferred Stock-
Change In Fair Value Of Derivative Liability-
Noncash Interest On Convertible Notes0.02
Interest Expense On Loan Payable-
Increase Decrease In Accrued Professional Fees-
Income taxes0.00
Increase (Decrease) in Accrued Investment Income Receivable0.00
Increase (Decrease) in Employee Related Liabilities0.23
Increase (Decrease) in Other Accounts Payable0.05
Increase (Decrease) in Other Accrued Liabilities0.02
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.01
Other Working Capital0.00
Other Noncash Expense0.04
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.03
Discontinued operations0.00
Net Cash flow from Operating Activities0.00
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Business Combination Acquisition Related Costs-
Crossflo Acquisition Liability-
Business Combination Consideration Transferred Liabilities Incurred-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Tax Benefit From Stock Options Exercised-
Tax Benefit From Stock Options Exercised-
Stock Issued During Period Value Stock Options Exercised-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow0.00
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Mosaic Immunoengineering Inc cash flow history.

Sign In Create Free Account

About Mosaic Immunoengineering Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001683168-26-006426

Figures are derived from filed reports and may be restated. Historical data is subject to revision.